Thyroidectomy-Specific Quality Improvement Measures ID'd

Share this content:
Thyroidectomy-Specific Quality Improvement Measures ID'd
Thyroidectomy-Specific Quality Improvement Measures ID'd

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- For patients undergoing thyroidectomy, hypocalcemia and recurrent laryngeal nerve (RLN) injury may be useful quality improvement measures, according to a study published online Nov. 29 in JAMA Surgery.

Jason B. Liu, M.D., from the American College of Surgeons in Chicago, and colleagues examined whether thyroidectomy-specific outcomes vary among hospitals in a retrospective cohort study involving 14,540 patients undergoing thyroidectomies at 98 hospitals.

The researchers found that clinically severe hypocalcemia occurred in 450 patients, RLN injury in 755 patients, and hematoma in 175 patients. There was variation in hospital performance for hypocalcemia and RLN injury, but not for hematoma. Inclusion of thyroidectomy-specific data in risk adjustment did not affect the rankings of hospital performance. Patients undergoing thyroidectomies at the best- versus the worst-performing hospitals less often had their postoperative parathyroid hormone level measured and were more often prescribed calcium, vitamin D, or both. Use of energy devices and intraoperative nerve monitoring were more prevalent at the best- versus worst-performing hospitals when profiled by RLN injury.

"Postoperative hypocalcemia and RLN injury, but not hematoma, potentially could be used as thyroidectomy-specific national hospital quality improvement metrics," the authors write. "Strategies aimed at reducing these complications after thyroidectomy may improve the care of these patients."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »